CA Patent

CA3154278A1 — Phosphodiesterase inhibitors

Assigned to University of Nebraska System · Expires 2020-04-16 · 6y expired

What this patent protects

Provided herein are compounds and methods for modulating the phosphodiesterase PDE4. More particularly, provided are selective inhibitors PDE4 and the uses of such inhibitors in regulating diseases and disorders, e.g., to treat cancer, inflammatory diseases, neurological diseases…

USPTO Abstract

Provided herein are compounds and methods for modulating the phosphodiesterase PDE4. More particularly, provided are selective inhibitors PDE4 and the uses of such inhibitors in regulating diseases and disorders, e.g., to treat cancer, inflammatory diseases, neurological diseases, neurodegenerative diseases, and addiction.

Drugs covered by this patent

Patent Metadata

Patent number
CA3154278A1
Jurisdiction
CA
Classification
—
Expires
2020-04-16
Drug substance claim
No
Drug product claim
No
Assignee
University of Nebraska System
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.